Cyclosporine and coronary outcomes in Kawasaki disease

Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): A randomized controlled, open-label blinded endpoints, phase 3 trial. Lancet 2019;393:1128-37.

Source: The Journal of Pediatrics - June 21, 2019 Category: Pediatrics Authors: Jane C. Burns Tags: Current Best Evidence Source Type: research